🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

951 results for “Eli” Clear

  1. A study in subjects with gout flares that investigates the effect, safety, tolerability, and pharmacokinetics (absorption, distribution, metabolism, and elimination) of a single dose of LEO 158968, a new compound that may potentially be used in the treatment of several autoinflammatory diseases

    LEO Pharma A/S

    Gout flares

    phase 1 other active

    1 trial

  2. A study investigating the safety, absorption, and elimination of NNC0705-0001, a new compound that could potentially be used in the treatment of cardiometabolic diseases caused by inflammation.

    NovoThirteen

    Cardiometabolic diseases with an inflammatory component

    phase 1 other active

    1 trial

  3. A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity

    Hoffmann-La Roche

    Healthy volunteers

    phase 1 other active

    1 trial

  4. A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  5. A study investigating the safety, absorption, and elimination of RO7795081, a new compound that may potentially be used in the treatment of type 2 diabetes and weight control

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  6. A study investigating the safety, absorption, and elimination of radioactively labeled RO7269162, a new compound that may potentially be used in the treatment of Alzheimer’s disease.

    Hoffmann-La Roche

    Healthy males volunteers

    phase 1 other active

    1 trial

  7. A study investigating the safety, tolerability, metabolism, and elimination of INE963, a new compound in the treatment of malaria.

    Novartis Pharmaceuticals

    Malaria

    phase 1 other active

    1 trial

  8. A study of LOXO-783 in Patients with PIK3CA H1047R-Mutant Advanced Breast Cancer and Other Solid Tumors.

    Eli Lilly Co.

    Advanced Breast Cancer and Other Solid Tumors

    phase 1 other active

    1 trial

  9. A study of the PAN-KRAS inhibitor LY4066434 in participants with KRAS mutant solid tumors.

    Eli Lilly Co.

    Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor Metastatic Solid Tumor, PanKRAS.

    phase 1 other active

    1 trial

  10. A study to assess the pharmacokinetics, and glucodynamics of LY3209590 in participants with type 2 diabetes

    Eli Lilly Co.

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  11. A study to assess the safety and tolerability of next-generation neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) therapy. NEXTGEN-TIL-ACT

    The George Institute

    Advanced epithelial tumors and immune checkpoint blockade (ICB) resistant solid tumors

    phase 1 other active

    1 trial

  12. A study to characterise the safety, tolerability and efficacy of LY3962673 in subjects with advanced solid tumors.

    Eli Lilly Co.

    KRAS G12D-mutant solid tumors.

    phase 1 other active

    1 trial

  13. A study to characterise the safety, tolerability and efficacy of LY4170156 in subjects with advanced solid tumors

    Eli Lilly Co.

    Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lung cancer, triple-negative breast cancer, pancreatic cancer and colorectal cancer.

    phase 1 other active

    1 trial

  14. A study to evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and preliminary Anti-Tumor activity of RO7616789 in participants with Advanced Small Cell Lung Cancer and other Neuroendocrine Carcinomas

    Hoffmann-La Roche

    Small Cell Lung Cancer and Neuroendocrine Carcinoma

    phase 1 other active

    1 trial

  15. Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

    Eli Lilly Co.

    Prostatic Neoplasms

    phase 1 other active

    1 trial

  16. Adebrelimab

    The First People's Hospital of Lianyungang

    Biliary Tract Malignancies

    phase 1 small molecule active

    1 trial

  17. Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)

    United Therapeutics Europe Ltd

    Urothelial Carcinoma

    phase 1 mab active

    1 trial

  18. An Open-Label, Phase 1b Study to Evaluate Safety, Tolerability and Preliminary Activity of the CTPS1 Inhibitor STP938 in Adult Subjects with High Risk Essential Thrombocythaemia who are Resistant to or Intolerant of Hydroxycarbamide Therapy. The VECTRA Study

    Lacuna Pharma Pty Ltd

    Thrombocythaemia

    phase 1 other active

    1 trial

  19. An open, single arm, single-center, Phase 1 trial investigating the effect of 7-days-repeated administration of linaprazan glurate on the pharmacokinetics of repeated doses of an approved antibiotic in healthy participants

    Lacuna Pharma Pty Ltd

    Helicobacter pylori infection, GERD

    phase 1 other active

    1 trial

  20. An open-label, DDI study to investigate the effects of amlitelimab on the PK of selected cytochrome P450 substrates

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 1 other active

    1 trial

  21. Anagrelide 0.5 mg

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  22. Bioequivalence of two transdermal therapeutic systems delivering 100 mcg/h fentanyl

    Alphapharm Pty Ltd

    Bioequivalence trial in healthy volunteers

    phase 1 other active

    1 trial

  23. Bioequivalence of two transdermal therapeutic systems delivering 100 mcg/h fentanyl

    Alphapharm Pty Ltd

    Bioequivalence trial in healthy volunteers

    phase 1 other active

    1 trial

  24. CERE-110: Adeno-Associated Virus Delivery of NGF

    SANGAMO THERAPEUTICS, INC

    Alzheimer's Disease

    phase 1 gene therapy completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources